JP2021534138A - オメカムチブメカルビルの塩及び結晶形態 - Google Patents

オメカムチブメカルビルの塩及び結晶形態 Download PDF

Info

Publication number
JP2021534138A
JP2021534138A JP2021507456A JP2021507456A JP2021534138A JP 2021534138 A JP2021534138 A JP 2021534138A JP 2021507456 A JP2021507456 A JP 2021507456A JP 2021507456 A JP2021507456 A JP 2021507456A JP 2021534138 A JP2021534138 A JP 2021534138A
Authority
JP
Japan
Prior art keywords
omecamtibu
mecalvir
xrpd
acid
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534138A5 (https=
JPWO2020037164A5 (https=
Inventor
モリソン，ヘンリー
ツゥイ，シェン
クアスドルフ，カイル
ヤーネス，エブリン
クアン，ビン・ピーター
ケリー，ロン・シー
カイエ，セバスチャン
シャオ，リンユン
ピアソン，デイビッド
レイバーン，ジャクリン
ゴライトリー，エイルサ
モーガン，ブラッドリー
ピーターソン，マシュー
エーベルリン，アレックス
オブルゾフ，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of JP2021534138A publication Critical patent/JP2021534138A/ja
Publication of JP2021534138A5 publication Critical patent/JP2021534138A5/ja
Publication of JPWO2020037164A5 publication Critical patent/JPWO2020037164A5/ja
Priority to JP2024090471A priority Critical patent/JP2024123028A/ja
Priority to JP2025066074A priority patent/JP2025108571A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • C07C309/08—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021507456A 2018-08-17 2019-08-16 オメカムチブメカルビルの塩及び結晶形態 Pending JP2021534138A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024090471A JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態
JP2025066074A JP2025108571A (ja) 2018-08-17 2025-04-14 オメカムチブメカルビルの塩及び結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765090P 2018-08-17 2018-08-17
US62/765,090 2018-08-17
PCT/US2019/046726 WO2020037164A1 (en) 2018-08-17 2019-08-16 Salts and crystal forms of omecamtiv mecarbil

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090471A Division JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態

Publications (3)

Publication Number Publication Date
JP2021534138A true JP2021534138A (ja) 2021-12-09
JP2021534138A5 JP2021534138A5 (https=) 2022-08-22
JPWO2020037164A5 JPWO2020037164A5 (https=) 2022-08-22

Family

ID=67809688

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021507456A Pending JP2021534138A (ja) 2018-08-17 2019-08-16 オメカムチブメカルビルの塩及び結晶形態
JP2024090471A Withdrawn JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態
JP2025066074A Pending JP2025108571A (ja) 2018-08-17 2025-04-14 オメカムチブメカルビルの塩及び結晶形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024090471A Withdrawn JP2024123028A (ja) 2018-08-17 2024-06-04 オメカムチブメカルビルの塩及び結晶形態
JP2025066074A Pending JP2025108571A (ja) 2018-08-17 2025-04-14 オメカムチブメカルビルの塩及び結晶形態

Country Status (8)

Country Link
US (2) US11465969B2 (https=)
EP (1) EP3837009A1 (https=)
JP (3) JP2021534138A (https=)
AU (2) AU2019321573B2 (https=)
CA (1) CA3108800A1 (https=)
MA (1) MA53226A (https=)
MX (2) MX2021001792A (https=)
WO (1) WO2020037164A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
DK2970123T4 (da) 2013-03-14 2026-01-26 Amgen Inc Krystallinsk dihydrochloridhydratsalt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
SMT202100472T1 (it) 2017-06-30 2021-09-14 Amgen Inc Sintesi di omecamtiv mecarbil
EP4512470A3 (en) 2017-06-30 2025-04-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
AU2018332887B2 (en) 2017-09-13 2022-12-08 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
EP3594199B1 (en) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
JP2021534138A (ja) * 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
US20220348543A1 (en) * 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) * 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220402874A1 (en) * 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US12194039B2 (en) 2020-11-12 2025-01-14 Amgen Inc Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
JP7843295B2 (ja) 2021-03-10 2026-04-09 アムジェン インコーポレイテッド オメカムチブメカルビルの合成
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
JP2016519071A (ja) * 2013-03-14 2016-06-30 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び塩を調製するプロセス

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
CA2902424A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX379899B (es) 2015-06-26 2025-03-11 Cytokinetics Inc Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal
EP4512470A3 (en) 2017-06-30 2025-04-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
SMT202100472T1 (it) 2017-06-30 2021-09-14 Amgen Inc Sintesi di omecamtiv mecarbil
EP3594199B1 (en) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) * 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070124A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CN115279349A (zh) 2020-02-10 2022-11-01 安进股份有限公司 奥美卡替莫卡必尔片剂
US12194039B2 (en) 2020-11-12 2025-01-14 Amgen Inc Methods of treating heart failure by administering omecamtiv mecarbil
JP7843295B2 (ja) 2021-03-10 2026-04-09 アムジェン インコーポレイテッド オメカムチブメカルビルの合成

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
JP2016519071A (ja) * 2013-03-14 2016-06-30 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び塩を調製するプロセス

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAIRA, M.R.: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, JPN6014016881, 1998, pages 163 - 208, ISSN: 0005254941 *
STAHL, P. HEINRICH; WERMUTH, CAMILLE G., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION, AND USE, JPN7023002973, 2002, pages 329 - 350, ISSN: 0005254942 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN7023002974, 20 September 2002 (2002-09-20), pages 305 - 317, ISSN: 0005254943 *

Also Published As

Publication number Publication date
CA3108800A1 (en) 2020-02-20
JP2024123028A (ja) 2024-09-10
US20240199550A1 (en) 2024-06-20
EP3837009A1 (en) 2021-06-23
JP2025108571A (ja) 2025-07-23
AU2019321573B2 (en) 2025-05-29
US20210221771A1 (en) 2021-07-22
MA53226A (fr) 2021-11-24
US11465969B2 (en) 2022-10-11
MX2021001792A (es) 2021-05-27
AU2019321573A1 (en) 2021-03-04
US20230108971A1 (en) 2023-04-06
MX2023013372A (es) 2023-11-27
AU2025204014A1 (en) 2025-06-19
US11926592B2 (en) 2024-03-12
WO2020037164A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
JP2021534138A (ja) オメカムチブメカルビルの塩及び結晶形態
US10590089B2 (en) Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR102498693B1 (ko) 정제 조성물
KR102841419B1 (ko) sGC 자극제를 포함하는 고체 분산물
JP2019048830A (ja) 複素環式化合物及びそれらの使用
US20230203009A1 (en) Pralsetinib pharmaceutical compositions
JP7825954B2 (ja) Ｍｃｌ－１阻害剤処方物
CN113330007A (zh) 尼拉帕利游离碱的晶体形式
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
US20230040902A1 (en) Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof
US12612366B2 (en) Salts and crystal forms of omecamtiv mecarbil
JP2013502427A (ja) アナバセイン化合物の制御放出製剤およびその使用
CA3210612C (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
HK40045152B (zh) 结晶丙二酸肾上腺素盐

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206